Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study

Abstract Background The recurrence rate of cholangiocarcinoma (CCA) is high, and there are currently no evidence-based treatments for recurrent CCA. This study aimed to evaluate the effectiveness and safety of programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibito...

全面介紹

書目詳細資料

Principais autores:	Lihui Lin, Yansong Lin, Wei Chen, Xia Yang, Xianwen Guo, Yanqin Wu, Xiaoyu Yin, Zhen Ding, Jingping Yun
格式:	Artigo
語言:	Inglês
出版:	BMC 2025-07-01
叢編:	BMC Cancer
主題:	Cholangiocarcinoma Recurrent PD-1 PD-L1 Efficacy Safety
在線閱讀:	https://doi.org/10.1186/s12885-025-14459-4
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!